# YPrime eCOA vs Shared Investigator Platform

The clearest difference is review sentiment: Shared Investigator Platform at 100% against YPrime eCOA's 13%. Shared Investigator Platform also leads on rating (5.0 vs 2.9). YPrime eCOA's advantage is update cadence (every 2 months vs every 6 months) and ratings volume (15 vs 5). On price, ads, in-app purchases and monetization model there is nothing between them.

Both are free to download. Neither carries in-app purchases, so what you see is what you pay.

Shared Investigator Platform holds the better App Store score, 5.0 against 2.9. Both are backed by a comparable volume of ratings — 15 and 5 respectively. Written reviews point the same way: 13% of YPrime eCOA's written reviews are positive against 100% of Shared Investigator Platform's.

YPrime eCOA ships an update every 2 months, Shared Investigator Platform every 6 months. The most recent releases landed on October 24, 2026 and October 27, 2026 respectively.

## The numbers

| Metric | YPrime eCOA | Shared Investigator Platform |
| --- | --- | --- |
| Price | Free | Free |
| Rating | [2.9 (15 ratings)](https://appshunter.io/ios/app/yprime-ecoa/id1521277112/reviews) | **[5.0 (5 ratings)](https://appshunter.io/ios/app/shared-investigator-platform/id6450245868/reviews)** |
| Number of ratings | **15** | 5 |
| Positive reviews | 12.5% of reviews | **100.0% of reviews** |
| In-app purchases | No | No |
| Ads | No | No |
| Update frequency | **Every 2 months** | Every 6 months |
| Monetization | Free | Free |
| Size | 131 MB | 49 MB |
| Requires iOS | **12.0** | 15.6 |
| Devices | iPhone, iPad, iPod | iPhone, iPad, iPod |
| Age rating | 4+ | 17+ |
| Developer | [Y-Prime](https://appshunter.io/developer/872635320) | [Cognizant Technology Solutions](https://appshunter.io/developer/387144373) |

## What reviewers say

### YPrime eCOA

[App page](https://appshunter.io/ios/app/yprime-ecoa/id1521277112)

Access clinical study questionnaires on your personal device. Use your enrollment ID to log in and complete required training. The app reminds you of upcoming questionnaires based on your visit schedule, ensuring compliance with study requirements.

**Highlights:** Access study questionnaires, Personal device access, Enrollment ID login, Study-specific questionnaires, Visit schedule reminders, Compliance tracking

**In-app purchases:** none


### Shared Investigator Platform

[App page](https://appshunter.io/ios/app/shared-investigator-platform/id6450245868)

This mobile application allows clinical trial site users to manage their actions on the Shared Investigator Platform. It facilitates easy login, E-signing, reviewing pending actions, accepting study invitations, and managing study staff. Users can also access study documents, complete tasks, and receive important notifications.

**Highlights:** User-friendly interface, E-sign functionality, Biometric authentication, Review pending actions, Accept study invitations, Manage study staff, Access study documents

**Features:** Vision Pro support

**In-app purchases:** none


## Frequently asked questions

### Is YPrime eCOA free?

YPrime eCOA is free to download, with no in-app purchases.

### Is Shared Investigator Platform free?

Shared Investigator Platform is free to download, with no in-app purchases.

### Which has better reviews, YPrime eCOA or Shared Investigator Platform?

Shared Investigator Platform is rated higher. YPrime eCOA averages 2.9 out of 5 from 15 ratings, while Shared Investigator Platform averages 5.0 from 5 ratings.

### Do YPrime eCOA or Shared Investigator Platform have ads?

Neither YPrime eCOA nor Shared Investigator Platform shows ads.

### Which is updated more often, YPrime eCOA or Shared Investigator Platform?

YPrime eCOA ships an update every 2 months, and Shared Investigator Platform every 6 months. Most recently, YPrime eCOA was updated on October 24, 2026 and Shared Investigator Platform on October 27, 2026.

---

*Compared by [AppsHunter](https://appshunter.io/) from daily US App Store data. Review summaries are generated from verbatim App Store reviews.*